Does legalizing cannabis increase consumption?
More than two years of research and studies summarized in the headline «Legalizing cannabis may increase its use.» That’s how the media has covered the Cannalex study, which we reported on report here. FranceInfo / AlloDocteurs, Release, Le Parisien, all these headlines, which cited an AFP news dispatch, focused on just one piece of data: the increase in cannabis use following legalization. At the risk of overlooking the rest.
Does the legalization of cannabis increase its use?
As reported in the Cannalex study, the legalization of cannabis has led to «an increase in the prevalence of use among adults» (more adults are using it) in the past month and in the past year (both regular and occasional use).
Among minors, Cannalex reports «stable prevalence rates of cannabis use.» The legalization of cannabis does not encourage minors to use it, but their use does not drop dramatically either. The most recent data show that, at the federal level, young Americans have never consumed so little cannabis in the past 20 years. In Colorado, 30-day prevalence among young people fell from 22% in 2011 to 21.2% in 2015. In Washington, the government's latest report also shows that consumption has declined among younger people and is increasing among adults.
Several factors generally explain the increase in use among adults. On the one hand, there are users who have «come out of the closet»—those who did not admit to their use before it became legal—and, on the other hand, there are new users. To our knowledge, the breakdown between these two groups has not been measured. But as is often the case, more complex attitudes lie behind the numbers.
The most important thing is that cannabis use among young people isn't increasing. They are the population most at risk from cannabis, and liberalizing the market does not, in principle, encourage them to use it. So why all the hatred?
Is the rise in cannabis use a serious problem?
All of this data points to from the most recent study on the use of cannabis following its legalization for medical purposes in U.S. states. The study, published in the journal Addiction, is summarized as follows: The legalization of medical cannabis is associated with higher rates of cannabis use but not with problematic use.
And that is what most French media outlets fail to point out. Cannabis is not a harmless substance, just like alcohol, cigarettes, or sugar, but failing to distinguish between its use and problematic use amounts to falling into the trap of prohibition.
Yes, long-term cannabis use in high doses can be harmful to the user. Yes, cannabis can be dangerous for young people. No, cannabis use comparable to «recommended» doses of alcohol among people over the age of 25 is not problematic.
Focusing solely on consumption rates means overlooking the broader issues surrounding legalization, and the conclusion of the Cannalex study presented by David Weinberger at the conference was very clear on this point. Legalizing cannabis means addressing three key areas: public health, safety, and economic issues. There is no perfect model at this time, and the most objective assessment must be based on a cost-benefit analysis.
Establish a system that would provide greater protection for consumers (quality-tested products, retail outlets), while regulating production and distribution (a regulatory framework for the industry), with legal businesses that pay taxes—even if this means more consumers—while addressing problematic consumption and keeping minors away through preventive measures—would that be worse than the current situation?
The comparison Christian Ben Lakdhar drew when discussing potential cannabis regulation in France with the legalization of online gambling is one part of the answer. The various experiments with decriminalization and legalization carried out in other countries are another.
-
Cannabis in Europe4 weeks ago
Bosnia and Herzegovina Continues to Roll Out Medical Cannabis Following Its Legalization
-
Cannabis in France3 weeks ago
France Submits the Long-Awaited Decree on the Reimbursement of Medical Cannabis to the Council of State
-
Cannabis in the U.S.4 weeks ago
The DEA Begins Hearings on the Federal Rescheduling of Cannabis
-
Business3 weeks ago
China Invests $10 Million in Medical Cannabis in Lebanon
-
Cannabis in Thailand4 weeks ago
Thailand Threatens Cannabis Shops with Severe Penalties
-
Business4 weeks ago
The British medical cannabis market is expected to exceed 140,000 patients by 2026
-
Cannabis in Australia2 weeks ago
South Australia is working to identify more water-efficient hemp varieties
-
Exchange4 weeks ago
Glass House will be the second U.S. cannabis company to list on the New York Stock Exchange


You must be logged in to post a comment Login